VarmX, a young Leiden-based biotech company committed to advancing therapies in the field of hemostasis and thrombosis, proudly announces a successful funding round in which it raised €15 million. This latest capital infusion underscores the firm’s vision and the investment community’s confidence in its innovative approach. Building on its strong foundation as a spin-off from Leiden University Medical Center (LUMC), VarmX is dedicated to developing therapeutic proteins that restore hemostasis, particularly in patients requiring emergency interventions or bleeding management during surgery. Its flagship compound, VMX-C001, is engineered to safely and effectively counteract the effects of oral factor Xa inhibitors—a critical need given the growing patient population affected by these medications.
The new funding will be strategically directed towards enhancing the development pathway of VMX-C001, accelerating the investigational new drug (IND) application process, and gearing up for pivotal clinical trials. This effort aims to expedite the translation of breakthrough science into tangible treatments that could dramatically improve patient outcomes. The announcement follows a series of successful financing milestones, with a €32 million Series B round completed in 2020 and another €32 million in the Series B2 round in May 2023, both of which laid the groundwork for VarmX's current trial preparations. With the additional €15 million, VarmX is poised to further refine its therapeutic protein platforms and expand its research and development capabilities, reinforcing its commitment to addressing unmet clinical needs in hemostasis and thrombosis while fostering innovation in the biotech landscape. For further details about their mission and progress, visit www.varmx.com.
